keyword
MENU ▼
Read by QxMD icon Read
search

Ovarian cancer treatment summary

keyword
https://www.readbyqxmd.com/read/29658612/let-7d-3p-is-associated-with-apoptosis-and-response-to-neoadjuvant-chemotherapy-in-ovarian-cancer
#1
Raúl García-Vázquez, Dolores Gallardo Rincón, Erika Ruiz-García, Abelardo Meneses García, Olga N Hernández De La Cruz, Horacio Astudillo-De La Vega, David Isla-Ortiz, Laurence A Marchat, Yarely M Salinas-Vera, Ángeles Carlos-Reyes, Sullivan López-González, Rosalio Ramos-Payan, César López-Camarillo
Altered expression of microRNAs contributes to the heterogeneous biological behavior of human malignancies and it may correlate with the clinical pathological features of patients. The let-7 microRNA family is frequently downregulated in human cancers and its aberrant expression may be a useful marker for prediction of the clinical response to therapy in patients. In the present study, we analyzed the expression of three members of the let-7 family (let-7a-3p, let-7d-3p and let-7f), which remains largely uncharacterized in ovarian cancer tissues...
April 12, 2018: Oncology Reports
https://www.readbyqxmd.com/read/29650751/fda-approval-summary-niraparib-for-the-maintenance-treatment-of-patients-with-recurrent-ovarian-cancer-in-response-to-platinum-based-chemotherapy
#2
Gwynn Ison, Lynn J Howie, Laleh Amiri-Kordestani, Lijun Zhang, Shenghui Tang, Rajeshwari Sridhara, Vadryn Pierre, Rosane Charlab, Anuradha Ramamoorthy, Pengfei Song, Fang Li, Jingyu Yu, Wimolnut Manheng, Todd R Palmby, Soma Ghosh, Hisani N Horne, Eunice Y Lee, Reena Philip, Kaushalkumar Dave, Xiao Hong Chen, Sharon L Kelly, Kumar G Janoria, Anamitro Banerjee, Okponanabofa Eradiri, Jeannette Dinin, Kirsten B Goldberg, William F Pierce, Amna Ibrahim, Paul G Kluetz, Gideon M Blumenthal, Julia A Beaver, Richard Pazdur
The Food and Drug Administration approved niraparib, a poly ADP ribose polymerase (PARP) inhibitor, on March 27, 2017, for maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response to platinum-based chemotherapy. Approval was based on data from the NOVA trial comparing niraparib with placebo in two independent cohorts, based on germline BRCA mutation status (gBRCAm vs. non-gBRCAm). Progression-free survival (PFS) in each cohort was the primary endpoint...
April 12, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29498639/the-oncolytic-virus-vsv-gp-is-effective-against-malignant-melanoma
#3
Janine Kimpel, Carles Urbiola, Iris Koske, Reinhard Tober, Zoltan Banki, Guido Wollmann, Dorothee von Laer
Previously, we described VSV-GP, a modified version of the vesicular stomatitis virus, as a non-neurotoxic oncolytic virus that is effective for the treatment of malignant glioblastoma and ovarian cancer. Here, we evaluate the therapeutic efficacy of VSV-GP for malignant melanoma. All of the human, mouse, and canine melanoma cell lines that were tested, alongside most primary human melanoma cultures, were infected by VSV-GP and efficiently killed. Additionally, we found that VSV-GP prolonged the survival of mice in both a xenograft and a syngeneic mouse model...
March 2, 2018: Viruses
https://www.readbyqxmd.com/read/29441937/antisense-lncrna-as-slc7a11-suppresses-epithelial-ovarian-cancer-progression-mainly-by-targeting-slc7a11
#4
Jinjin Yuan, Zongwen Liu, Rui Song
Antisense lncRNAs play a key role in the progression of multiple cancers. Thus, it is important to elucidate the function and mechanism of antisense lncRNAs, which may play a role in the treatment of epithelial ovarian cancer (EOC). In the current study, for the first time, we showed that the level of As-SLC7A11 was markedly reduced in EOC cancer tissues and cell lines compared with those of normal control. Further study showed that silencing of As-SLC7A11 could enhance ovarian cancer cell migration. In comparison, overexpression of As-SLC7A11 markedly induced ovarian cancer cell apoptosis...
July 3, 2017: Die Pharmazie
https://www.readbyqxmd.com/read/29221134/a-trna-fragment-trf5-glu-regulates-bcar3-expression-and-proliferation-in-ovarian-cancer-cells
#5
Kun Zhou, Kevin W Diebel, Jon Holy, Andrew Skildum, Evan Odean, Douglas A Hicks, Brent Schotl, Juan E Abrahante, Monique A Spillman, Lynne T Bemis
Ovarian cancer is a complex disease marked by tumor heterogeneity, which contributes to difficulties in diagnosis and treatment. New molecular targets and better molecular profiles defining subsets of patients are needed. tRNA fragments (tRFs) offer a recently identified group of noncoding RNAs that are often as abundant as microRNAs in cancer cells. Initially their presence in deep sequencing data sets was attributed to the breakdown of mature tRNAs, however, it is now clear that they are actively generated and function in multiple regulatory events...
November 10, 2017: Oncotarget
https://www.readbyqxmd.com/read/29187451/cold-atmospheric-plasma-cap-and-cap-stimulated-cell-culture-media-suppress-ovarian-cancer-cell-growth-a-putative-treatment-option-in-ovarian-cancer-therapy
#6
Dominique Koensgen, Ilma Besic, Denis Gümbel, Anne Kaul, Martin Weiss, Karoline Diesing, Axel Kramer, Sander Bekeschus, Alexander Mustea, Matthias B Stope
BACKGROUND/AIM: Ovarian cancer (OC) is a gynecologic tumor with poor prognosis. Despite radical cytoreductive surgery and platinum-based adjuvant systemic treatment, OC will relapse in the majority of the cases. Thus, cold atmospheric plasma (CAP), a highly reactive physical state bearing diverse biological activities being suited for anticancer therapy, may be a promising option in OC therapy. MATERIALS AND METHODS: OC cell lines were exposed either directly to the CAP or to cell culture medium previously exposed to CAP...
December 2017: Anticancer Research
https://www.readbyqxmd.com/read/29163177/assessment-of-pharmacogenomic-panel-assay-for-prediction-of-taxane-toxicities-preliminary-results
#7
Raffaele Di Francia, Luigi Atripaldi, Salvo Di Martino, Carla Fierro, Tommaso Muto, Anna Crispo, Sabrina Rossetti, Gaetano Facchini, Massimiliano Berretta
Backbone: Paclitaxel and docetaxel are the primary taxane anticancer drugs regularly used to treat, breast, gastric, ovarian, head/neck, lung, and genitourinary neoplasm. Suspension of taxane treatments compromising patient benefits is more frequently caused by peripheral neuropathy and allergy, than to tumor progression. Several strategies for preventing toxicity have been investigated so far. Recently, findings on the genetic variants associated with toxicity and resistance to taxane-based chemotherapy have been reported...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/29146938/computational-investigation-of-homologous-recombination-dna-repair-deficiency-in-sporadic-breast-cancer
#8
Yue Wang, Matthew H Ung, Sharon Cantor, Chao Cheng
BRCAness has important implications in the management and treatment of patients with breast and ovarian cancer. In this study, we propose a computational framework to measure the BRCAness of breast and ovarian tumor samples based on their gene expression profiles. We define a characteristic profile for BRCAness by comparing gene expression differences between BRCA1/2 mutant familial tumors and sporadic breast cancer tumors while adjusting for relevant clinical factors. With this BRCAness profile, our framework calculates sample-specific BRCA scores, which indicates homologous recombination (HR)-mediated DNA repair pathway activity of samples...
November 16, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29100168/genetic-variants-as-ovarian-cancer-first-line-treatment-hallmarks-a-systematic-review-and-meta-analysis
#9
REVIEW
Joana Assis, Carina Pereira, Augusto Nogueira, Deolinda Pereira, Rafael Carreira, Rui Medeiros
BACKGROUND: The potential predictive value of genetic polymorphisms in ovarian cancer first-line treatment is inconsistently reported. We aimed to review ovarian cancer pharmacogenetic studies to update and summarize the available data and to provide directions for further research. METHODS: A systematic review followed by a meta-analysis was conducted on cohort studies assessing the involvement of genetic polymorphisms in ovarian cancer first-line treatment response retrieved through a MEDLINE database search by November 2016...
December 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29063517/parp-inhibitors-in-the-treatment-of-triple-negative-breast-cancer
#10
REVIEW
Jill J J Geenen, Sabine C Linn, Jos H Beijnen, Jan H M Schellens
Breast cancer is a heterogeneous disease, manifesting in a broad differentiation in phenotypes and morphologic profiles, resulting in variable clinical behavior. Between 10 and 20% of all breast cancers are triple negative. Triple-negative breast cancer (TNBC) lacks the expression of human epidermal growth factor receptor 2 (HER2) and hormone receptors; therefore, to date, chemotherapy remains the backbone of treatment. TNBC tends to be aggressive and has a high histological grade, resulting in a poor 5-year prognosis...
October 23, 2017: Clinical Pharmacokinetics
https://www.readbyqxmd.com/read/29022485/prevalence-of-%C3%AE-iii-tubulin-tubb3-expression-in-human-normal-tissues-and-cancers
#11
Fermín Person, Waldemar Wilczak, Claudia Hube-Magg, Christoph Burdelski, Christina Möller-Koop, Ronald Simon, Mercedes Noriega, Guido Sauter, Stefan Steurer, Susanne Burdak-Rothkamm, Frank Jacobsen
Microtubules are multifunctional cytoskeletal proteins that are involved in crucial cellular roles including maintenance of cell shape, intracellular transport, meiosis, and mitosis. Class III beta-tubulin (βIII-tubulin, also known as TUBB3) is a microtubule protein, normally expressed in cells of neuronal origin. Its expression was also reported in various other tumor types, such as several types of lung cancer, ovarian cancer, and esophageal cancer. TUBB3 is of clinical relevance as overexpression has been linked to poor response to microtubule-targeting anti-cancer drugs such as taxanes...
October 2017: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/28991639/haemanthamine-alters-sodium-butyrate-induced-histone-acetylation-p21-waf1-cip1-expression-chk1-and-chk2-activation-and-leads-to-increased-growth-inhibition-and-death-in-a2780-ovarian-cancer-cells
#12
Martina Seifrtová, Radim Havelek, Lucie Cahlíková, Daniela Hulcová, Naděžda Mazánková, Martina Řezáčová
BACKGROUND: Haemanthamine (HA) and sodium butyrate (NaB) are promising candidates for chemotherapy as a treatment for cancer. PURPOSE: We aimed to determine the anticancer potential of HA and NaB, alone and in combination, in A2780 ovarian cancer cells and concurrently investigated anticancer potential in contrast to non-cancer human MRC-5 fibroblasts. METHODS: Antiproliferative effects were determined by WST-1 assay and by Trypan blue exclusion staining...
November 15, 2017: Phytomedicine: International Journal of Phytotherapy and Phytopharmacology
https://www.readbyqxmd.com/read/28967908/using-a-novel-computational-drug-repositioning-approach-drugpredict-to-rapidly-identify-potent-drug-candidates-for-cancer-treatment
#13
A B Nagaraj, Q Q Wang, P Joseph, C Zheng, Y Chen, O Kovalenko, S Singh, A Armstrong, K Resnick, K Zanotti, S Waggoner, R Xu, A DiFeo
Computation-based drug-repurposing/repositioning approaches can greatly speed up the traditional drug discovery process. To date, systematic and comprehensive computation-based approaches to identify and validate drug-repositioning candidates for epithelial ovarian cancer (EOC) have not been undertaken. Here, we present a novel drug discovery strategy that combines a computational drug-repositioning system (DrugPredict) with biological testing in cell lines in order to rapidly identify novel drug candidates for EOC...
January 18, 2018: Oncogene
https://www.readbyqxmd.com/read/28831912/clinical-prognostic-and-therapeutic-significance-of-heat-shock-proteins-in-cancer
#14
Jasleen Saini, Pushpender K Sharma
Heat shock proteins (HSPs) constitute a group of proteins that play crucial role in process of proteins folding. HSPs are also known to modulate number of key apoptotic factors. High expression of these proteins is reported in array of cancers, such as breast, prostate, colorectal, lung, ovarian, gastric, oral and esophageal cancer. Ample amount of investigations carried out on variety of cancers suggests HSPs as a promising hallmark in cancers. Their expression profile in several tumors elucidates that they help in proliferation, invasion, metastasis and death of cancerous cells...
August 23, 2017: Current Drug Targets
https://www.readbyqxmd.com/read/28791374/corilagin-sensitizes-epithelial-ovarian-cancer-to-chemotherapy-by-inhibiting-snail%C3%A2-glycolysis-pathways
#15
Luoqi Jia, Jiayi Zhou, Hongbo Zhao, Hongyan Jin, Minzhi Lv, Naiqing Zhao, Zhizhong Zheng, Yiling Lu, Yanlin Ming, Yinhua Yu
We identified that corilagin is a major component extracted from a well-known hepatoprotective and antiviral medicinal herb, Phyllanthus niruri L with antitumor activity. Our previous study found that corilagin inhibited the growth of ovarian cancer cells via the TGF-β/AKT/ERK signaling pathways. Recently, we demonstrated that corilagin enhanced the sensitivity of ovarian cancer cells to chemotherapy. Ovarian cancer cell lines, SKOv3ip, Hey and HO-8910PM-Snail, were treated with different concentrations of corilagin in combination with paclitaxel and carboplatin...
August 7, 2017: Oncology Reports
https://www.readbyqxmd.com/read/28751443/fda-approval-summary-rucaparib-for-the-treatment-of-patients-with-deleterious-brca-mutation-associated-advanced-ovarian-cancer
#16
Sanjeeve Balasubramaniam, Julia A Beaver, Sara Horton, Laura L Fernandes, Shenghui Tang, Hisani N Horne, Jinzhong Liu, Chao Liu, Sarah J Schrieber, Jingyu Yu, Pengfei Song, William Pierce, Kim J Robertson, Todd R Palmby, Haw-Jyh Chiu, Eunice Y Lee, Reena Philip, Robert Schuck, Rosane Charlab, Anamitro Banerjee, Xiao Hong Chen, Xing Wang, Kirsten B Goldberg, Rajeshwari Sridhara, Geoffrey Kim, Richard Pazdur
On December 19, 2016, the FDA granted accelerated approval to rucaparib (RUBRACA; Clovis Oncology, Inc.) for the treatment of patients with deleterious BRCA mutation (germline and/or somatic)-associated advanced ovarian cancer who have been treated with two or more chemotherapies. The FDA also approved the FoundationFocus CDx BRCA test (Foundation Medicine, Inc.), the first next-generation sequencing-based companion diagnostic, for identifying patients with advanced ovarian cancer eligible for treatment with rucaparib based on detection of deleterious BRCA1 and/or BRCA2 mutations in tumor tissue...
December 1, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28705409/clinical-benefit-and-risk-of-death-with-endocrine-therapy-in-ovarian-cancer-a-comprehensive-review-and-meta-analysis
#17
REVIEW
Laura Paleari, Sara Gandini, Nicoletta Provinciali, Matteo Puntoni, Nicoletta Colombo, Andrea DeCensi
BACKGROUND: Steroid hormones promote epithelial ovarian cancer (EOC) growth and their receptor expression is associated with disease outcome. Hormone therapy is frequently used in pretreated EOC, but the magnitude of activity overall and by specific agents or tumor characteristics is unknown. METHODS: Clinical Benefit Rates (CBR) and deaths from clinical trials of endocrine agents were meta-analyzed. Summary estimates of CBR (SCBR) and Odd Ratio for death (SOR) were calculated according with type of drug, ER and PgR status, platinum resistance, line of therapy, tumor grade and tamoxifen dose...
September 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28671994/morphological-analysis-of-human-umbilical-vein-endothelial-cells-co-cultured-with-ovarian-cancer-cells-in-3d-an-oncogenic-angiogenesis-assay
#18
Xiao Wan, Phurit Bovornchutichai, Zhanfeng Cui, Eric O'Neill, Hua Ye
Antiangiogenic therapy for cancer is a strategy targeted at tumour vasculature, often in combination with conventional cytotoxicity treatments. Animal testing is still the most common method used for evaluating the efficacy of new drugs but tissue-engineered in vitro models are becoming more acceptable for replacing and reducing the use of animals in anti-cancer drug screening. In this study, a 3D co-culture model of human endothelial cells and ovarian cancer cells was developed. This model has the potential to mimic the interactions between endothelial cells and ovarian cancer cells...
2017: PloS One
https://www.readbyqxmd.com/read/28615526/identifying-prognostic-signature-in-ovarian-cancer-using-dirgenerank
#19
Jian-Yong Wang, Ling-Ling Chen, Xiong-Hui Zhou
Identifying the prognostic genes in cancer is essential not only for the treatment of cancer patients, but also for drug discovery. However, it's still a big challenge to select the prognostic genes that can distinguish the risk of cancer patients across various data sets because of tumor heterogeneity. In this situation, the selected genes whose expression levels are statistically related to prognostic risks may be passengers. In this paper, based on gene expression data and prognostic data of ovarian cancer patients, we used conditional mutual information to construct gene dependency network in which the nodes (genes) with more out-degrees have more chances to be the modulators of cancer prognosis...
July 11, 2017: Oncotarget
https://www.readbyqxmd.com/read/28551932/-hormone-replacement-therapy-after-gynecological-malignancies
#20
REVIEW
Nadav Michaan, Dan Grisaru
Treatment of gynecological malignancies can cause an abrupt onset of menopausal symptoms along with associated long term morbidity. Hormone replacement therapy (HRT) is the most effective treatment to alleviate these symptoms but the safety of HRT among gynecologic oncology patients remains controversial. We conducted a review of the published literature on the risk of recurrent disease among gynecologic cancer patients using HRT. Our research revealed a shortage of prospective, randomized trials on this important subject...
March 2017: Harefuah
keyword
keyword
24374
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"